Asset Details
Do you wish to reserve the book?
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Do you wish to request the book?
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
2015
Overview
A selective, small-molecule inhibitor of NLRP3 suppresses activation of the inflammasome
in vitro
and
in vivo
and attenuates inflammatory disease.
The NOD-like receptor (NLR) family, pyrin domain–containing protein 3 (NLRP3) inflammasome is a component of the inflammatory process, and its aberrant activation is pathogenic in inherited disorders such as cryopyrin-associated periodic syndrome (CAPS) and complex diseases such as multiple sclerosis, type 2 diabetes, Alzheimer's disease and atherosclerosis. We describe the development of MCC950, a potent, selective, small-molecule inhibitor of NLRP3. MCC950 blocked canonical and noncanonical NLRP3 activation at nanomolar concentrations. MCC950 specifically inhibited activation of NLRP3 but not the AIM2, NLRC4 or NLRP1 inflammasomes. MCC950 reduced interleukin-1β (IL-1β) production
in vivo
and attenuated the severity of experimental autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis. Furthermore, MCC950 treatment rescued neonatal lethality in a mouse model of CAPS and was active in
ex vivo
samples from individuals with Muckle–Wells syndrome. MCC950 is thus a potential therapeutic for NLRP3-associated syndromes, including autoinflammatory and autoimmune diseases, and a tool for further study of the NLRP3 inflammasome in human health and disease.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
/ 13/1
/ 13/106
/ 13/109
/ 13/21
/ 13/31
/ 13/95
/ 14
/ 14/19
/ 631/154
/ Animals
/ Carrier Proteins - antagonists & inhibitors
/ Cryopyrin-Associated Periodic Syndromes - drug therapy
/ Encephalomyelitis, Autoimmune, Experimental - drug therapy
/ Heterocyclic Compounds, 4 or More Rings - pharmacology
/ Heterocyclic Compounds, 4 or More Rings - therapeutic use
/ Humans
/ Inflammasomes - antagonists & inhibitors
/ Interleukin-1beta - drug effects
/ Mice
/ Neurons
/ NLR Family, Pyrin Domain-Containing 3 Protein
/ Proteins
